Clinical Trial Update: Nicotinamide as an Early Alzheimer's Disease Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nicotinamide as a treatment for Alzheimer's Disease and mild cognitive impairment has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Nicotinamide (nicotinamide)

Snippet

Sponsor: University of California, Irvine | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Status: COMPLETED | Results posted: 2023-10-17